A Phase 1 Study of ABI‐009 (Nab‐sirolimus) in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors—A Children's Oncology Group Pediatric Early Phase Clinical Trial Network Study ADVL1514

A Phase 1 Study of ABI‐009 (Nab‐sirolimus) in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors—A Children's Oncology Group Pediatric Early Phase Clinical Trial Network Study ADVL1514

ABSTRACT Background Nab‐sirolimus (ABI‐009, nab‐rapamycin; Aadi Bioscience Inc. [Aadi]) is a human albumin‐bound form of sirolimus nanoparticles, a potent mTOR inhibitor. This phase I trial was conducted to define dose‐limiting toxicities (DLT), maximum tolerated or recommended phase II dose (MTD/RP...

Full description

Saved in:
Bibliographic Details
Main Authors: Stuart L. Cramer, Alyssa Terry Reddy, Charles Gene Minard, Stephan Voss, Elizabeth Fox, Xiaowei Liu, Kristina Denic, Joel M. Reid, Brenda J. Weigel
Format: Article
Language:English
Published: Wiley 2024-11-01
Series:Cancer Medicine
Subjects:
ABI‐009
Clinical trial
nab‐rapamycin
Pediatrics
rapamycin
Online Access:https://doi.org/10.1002/cam4.70376
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.70376

Similar Items